HOME ASBESTOS DRUGS POLLUTANTS ACCIDENTS MALPRACTICE STORY OF OUR FIRM SEARCH

Mesothelioma Publication: Secreted Frizzled Related Protein

For Mesothelioma help, mesothelioma abstract of an an article published at PubMed by the NIH.

Cancer Res. 2005 Feb 1;65(3):743-8.

Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells.

He B, Lee AY, Dadfarmay S, You L, Xu Z, Reguart N, Mazieres J, Mikami I, McCormick F, Jablons DM.

Thoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California-San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA.

The secreted frizzled-related proteins (SFRPs) function as negative regulators of Wnt signaling and have important implications in tumorigenesis. Frequent promoter hypermethylation of SFRPs has been identified in human cancer. Restoration of SFRP function attenuates Wnt signaling and induces apoptosis in a variety of cancer types. Wnt signaling is known to inhibit apoptosis through activation of beta-catenin/Tcf-mediated transcription. Recently, we identified aberrant Wnt activation as a result of Dishevelled overexpression in malignant mesothelioma. Here, we report that silencing of SFRP4 is correlated with promoter hypermethylation in beta-catenin-deficient mesothelioma cell lines. Reexpression of SFRP4 in these beta-catenin-deficient mesothelioma cell lines blocks Wnt signaling, induces apoptosis, and suppresses growth. Conversely, knocking down SFRP4 by small interfering RNA in cell lines expressing both SFRP4 and beta-catenin stimulates Wnt signaling, promotes cell growth, and inhibits chemodrug-induced apoptosis. Our results suggest that methylation silencing of SFRP4 may play an important role in aberrant Wnt activation in mesothelioma even in the absence of beta-catenin. Our data also suggest that beta-catenin-independent noncanonical pathway(s) may be involved in the apoptotic inhibition caused by activation of Wnt signaling.


PMID: 15705870 [PubMed - indexed for MEDLINE]

For legal help anywhere in the U.S. call:

1 - 800 - 476 - 6070

Prior results do not guarantee a similar outcome.

ATTORNEY ADVERTISING

TABLE OF CONTENTS
Mesothelioma Mesothelioma Home Page
head Mesothelioma: An Overview
kleio The Clock Is Ticking
asbestos Our Toughest Cases
head Diagnosis
treatment Symptoms, Stages, Treatment
kleio Latest News
New York Numbers
Asbestos


IN THIS SECTION
Farnesyltransferase Inhibitors
Cancer Immunotherapy
Great Britain
Poland
Pemetrexed Therapy
Sv40 Specific Recall Immunity
Polish Cases
Extra Pleural Pneumonectomy
Intraoperative Radiation Therapy
Calretinin
Hyaluronan
Granulocyte Colony Stimulating Factor
Canada
Pemetrexed (Alimta)
Calretinin Antibodies
Greece
Neoplasia
FDA Pemetrexed
Secreted Frizzled Related Protein
Tumor Necrosis
Podoplanin
Lymphohistiocytoid
Pathogenesis of Malignant Pleural
Diagnostic Difficulties
Mesothelioma from Adenocarcinoma
Mesothelial Proliferation
ThinPrep Cytospin
Effusion
Chemotherapy Options
Heparanase
Malignant Deciduoid
Mortality
Pemetrexed in Malignant Pleural Mesothelioma
Pleural Mesothelioma
Prognostic Analysis
Italian Mortality Rates
Vinorelbine and Oxaliplatin
DNA Methylation Profiles
Primary Malignant Pericardial Mesothelioma
Abdominal CAT Scans
China
Disseminated Malignant
Statistical Validation
Pathogenesis
Lung Adenocarcinoma
Japan


RETURN BACK TO
Mesothelioma
Latest News
see also:

Farnesyltransferase Inhibitors Learn about mesothelioma and farnesyltransferase inhibitors
Do you know about Farnesyltransferase inhibitors and mesothelioma?

Lung Adenocarcinoma Pleural Mesothelioma Publication discusses lung adenocarcinoma
An abstract of Pleural Mesothelioma article on lung adenocarcinoma

Mesothelioma National Institute Health Publication The National Institute of Health Mesothelioma Research Publications
Mesothelioma Publications from the National Institute of Health